Agreement to manufacture Leucid Lead asset, LEU011 for the treatment of solid tumours and haematological malignancies utilising facilities and quality assurance services at the Zayed Centre for Research into Rare Disease in Children is first-of-its-kind. Leucid Bio to retain IP in respect of services arising from this venture. Leucid Bio expects to file its CTA […]
Co-founder and Chief Scientific Officer at Leucid Bio, Dr John Maher is revolutionising Chimeric Antigen Receptor (CAR) T-cell therapy, by designing CARs that are more powerful than predecessors and tough enough to tackle solid tumours. Dr Maher began his academic career at Trinity College, Dublin and has held numerous clinical, research and teaching positions at […]
Proprietary Lateral CAR Platform achieved pre-clinical proof-of-concept data demonstrating prolonged disease-free survival compared to other CAR T-cell products. Lead programme, LEU011 has completed pre-clinical development for the treatment of solid tumours and is in pre-clinical development for a range of haematological malignancies. Leucid expects to file its CTA to initiate the clinical trial in H1 […]
World Cancer Day is a moment when all of us stop and think of the impact that cancer has on our lives. As the second-leading cause of death worldwide, with 10 million people dying from cancer every year, cancer is a very present healthcare threat. [tag] Macmillan Cancer Support estimates that there are currently […]
New data highlight the strength and versatility of Leucid’s proprietary, next-generation technology pCAR has now achieved proof-of-concept across a range of co-stimulatory domains, binders, targets and target combinations in pre-clinical liquid and solid tumour cell lines/models John Maher has been an early pioneer of CAR T-cell immunotherapy with a focus on solid tumours London, UK […]